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Abstract: The use of neuroprotective therapies begs the question of how such therapies 
could affect preexisting stem cell populations within the host, as well as those introduced 
through cell-replacement therapy. Multiple mechanisms may mediate stem cell responses 
to  neuroprotectants  such  as  host/donor  age  and  gender,  cellular  lineage/differentiation 
status,  and  mitochondrial  dynamics.  Current  therapeutic  sources  for  stem  cells  are 
embryonic, somatic, or induced pluripotent, with very little known about the effects of 
gender,  age,  cell  type,  and  mitochondrial  dynamics.  With  the  advent  of  therapies  to 
stimulate and recruit endogenous stem cells or transplant donor cells into damage areas in 
the  hopes  of  recuperative  regeneration  of  lost  neurons,  it  is  important  to  discuss 
mechanisms that dictate the winning players in the neuroprotection game. This review will 
focus on our current understanding of the characteristics of renewing stem cells that may 
affect neuroprotection. 
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1. Introduction  
The potential impact of stem cell research was declared on the cover of Time magazine as the 
―coming revolution in stem cells‖ [1]. With new administrative initiatives and NIH guidelines in place, 
the race is on to establish new and valid stem cell lines for new cures. Fueling the revolution are 
billions of dollars in stem cells initiatives that over time will demand a return on investments [2]. So, it 
is important that we get it right. To do so, we must know the character and function of the stem cells 
used in treatment protocols. As so apply stated, ―…it will not be the cells themselves that will be so 




important, but rather what we learn about them and the way they function.‖ [3]. This review will touch 
on our expanding knowledge of certain less emphasized aspects of the stem cell character such as 
host/donor  age  and  gender,  cellular  lineage/differentiation  status,  telomerase,  and  mitochondrial 
dynamics. While knowledge of mitochondrial dynamics in renewing cells is expanding, less is known 
about how telomerase, age, and gender can influence therapeutic responses, dictate and/or modulate 
neuroprotective  responses.  Further,  we  know  very  little  about  how  these  characters  interact  and 
become diverse factors that induce alterations in stem cells or modulate their environment during 
renewal. The same stem cell characteristics that we seek to use to our advantage in neuroprotective 
treatments are the characteristics that can mediate disease states. Therefore, it is important that we 
recognize all stem cell characteristics and functions that could impact treatments, as well as serve to 
improve treatment protocols aimed at either preventing neurodegeneration or inducing neurogenesis. 
2. Multiple Mechanisms May Mediate Stem Cell Responses  
2.1. Stem Cell Types and Renewal 
A goal of neuroprotection is to restore or facilitate replacement of normal cell function, tissue, 
and/or organ due to damage [4]. Neural stem cells provide a renewable source of replacement cells, 
and increased proliferation of neural stem cells can act as a protective mechanism. Cells that renew 
themselves  and  ultimately  differentiate  do  so  through  cycles  of  asymmetrical  and  symmetrical 
divisions that ultimately creates a hierarchy of various cell types. These cells types can be derived from 
adult stem cells (ASC), tissue specific progenitor cells, somatic cell nuclear transfer (SCNT) cells, 
single cell embryo biopsy, arrested embryos, altered nuclear transfer cells, reprogramming somatic 
cells (IPS), and embryonic stem cells (ESC) [4]. Each source has advantages and limitations mediated 
by genetic and/or epigenetic factors [5]. More specifically, the advantages include pluripotency in ESC 
where cells can differentiate into all germ layers, multipotency in ASC where cells can differentiate 
into limited lineages, versus transdifferentiation where cells can differentiate into a different lineage 
than its original state (SCNT, IPS) [6]. However, advantages associated with plasticity, can become 
disadvantages associated with unlimited growth and tumor-forming potential [5].  
The mammalian central  nervous system  (CNS) contains  a hierarchy of self-renewing cells  that 
proliferate, and are multipotent for neuronal and glial sub-types, that then differentiate into lineage 
cells  (precursors  or  progenitors).  Lineage-specific  precursors  or  progenitors  include  neuronal, 
astroglial,  glial,  and  oligodendroglial  [7].  Cell  types,  within  the  stem  cell  hierarchy  that  include 
precursors and progenitors, can be identified by certain proteins characteristically expressed during 
renewal and differentiation (Figure 1). These characteristic proteins can influence cell fate and survival 
under certain environmental conditions or niche within regions of the brain [8]. Similarly, ESC are 
identified by certain expressed proteins that are not characteristic of ASC. More recently, microRNAs 
(miRNAs) profiles identified in ESC demonstrate gene expression patterns involved in renewal and/or 
differentiation  [9–11].  Further,  such  profiles  may  be  sex-specific  during  early  stages  of  
differentiation [12]. 
 




Figure 1. Replacement cells are provided through a hierarchy of cell types that result when 
self-renewing stem cells proliferate through asymmetrical and/or symmetrical division to 
form precursor and progenitor cells. Upon differentiation, neurons are formed. 
 
Acute neurological insults stimulate a basal rate of neural progenitor/precursor proliferation and 
differentiation [7,13]. This ability to repair damage due to loss of neurons may be dictated by the 
available neuronal precursor/progenitor and their mitogenic factors before repair can proceed [14].  
In the hippocampus, ASC give rise to both glial and neurons through hippocampal precursors [15,16]. 
Mitogenic  factors  such  as  epidermal  growth  factor  (EGF)  promote  proliferation  of  hippocampal 
precursors  in  serum  free  media,  and  aid  in  promoting  neural  stem  cell  renewal  [7,17].  EGF  acts 
through its respective receptor (EGFR) to induce receptor phosphorylation, then initiate intracellular 
signaling pathways that are involved in cell growth and physiology [18]. Studies indicate that EGF 
promotes  neurogenesis/self  repair,  and  correspondingly  EGFRs  are  unregulated  after  injury  [13].  
In  vitro  studies  using  primary  hippocampal  cultures  provide  relevant  characterization  of  cellular 
composition and mitogenic growth conditions that affect proliferation and/or differentiation during 
hippocampal renewal (Figure 2) [7,14,21]. 
2.2. Stem Cells Age 
Stem  and  progenitor  cells’  proliferation  potential  decreases  with  age,  and  thereby  make  them 
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studies  than  human,  the  frequency  and  rate  of  neurogenesis  as  well  as  self-renewal  and  mitotic 
potential of neural stem/progenitor cells in subventricular and subgranular zones decline with age [23–25]. 
Figure 2. Primary mouse hippocampal cells cultured in vitro on coverslips with (a) and 
without growth factors (GF) (b, c), then fixed and stained for neuronal cells with markers 
neurofilament (nF) red and glial cells with (GFAP) green (a, b), and neural cells MAP2 (c) 
with DAPI stained nuclei (blue). 
 
ESC, FSC, and young and old ASC are maintained by differing renewal programs that change over 
time  in  response  to  tissue  growth,  damage,  and  repair  [26].  In  addition,  declining  trophic/growth 
factors may play a role in age related loss of stem cells [14]. Li et al. propose that stem cell aging may 
be heterogeneous  among individuals,  with  some individuals  having an advantage over aging  with 
any/or  all  aspects  of  sustained  neurogenesis,  promotion  of  differentiation,  enhancement  of 
proliferation, and facilitation of neural plasticity [27]. It was suggested by studies using mice generated 
neurospheres that aging may lead to mutational load within the stem cell compartment [28]. 
2.3. Telomerase “Immortality” 
An important factor related to neural stem cell aging is telomerase activity. Telomerase is active 
during embryogenesis and therefore active in ESC. It becomes inactive in postnatal somatic tissues, 
but maintains low activity in renewing basal ASC found in the subgranular zone of the hippocampal 
and dentate gyrus [29]. During renewal, telomere maintenance may be essential for prolonged stem 
cell function [30–32]. While telomerase is important in maintaining chromosomal integrity and cell 
viability in these stem-cell reserves, it cannot maintain telomeres. Therefore, telomeres will continue to 
shorten during ageing and/or replicative stress [25,29,33]. During neurogenesis, telomerase is active in 
renewing  stem  cells,  down  regulated  during  differentiation,  and  if  overexpressed  inhibits 
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differentiation [34]. All of these studies beg the question of what happens with telomerase in IPS 
and/or SCNT cells, and does the age of donor matter? Will we need to screen donors for telomere 
length to optimize our stem cells? If we know our donor has short telomeres does that make them a 
poor donor and would that be similar to transplanting a damaged heart? 
Human  population  studies  show  telomere  maintenance  and  telomerase  length  or  reserve  is 
important in healthy lifespan and is linked with better cognitive function [25]. Studies in telomerase 
knockout mice showed that neural stem cell renewal and differentiation was compromised in aged 
mice [25]. Further, studies of ageing syndromes indicate association with telomere dysfunction and 
that  stem  cells  may  be  more  sensitive  to  telomere  dysfunction  based  on  cell  type  and  
environment [25,29]. Through telomerase dysfunction, ageing stem cells can become susceptible to 
transformation. Add to all this, genomic integrity as guarded by p53, which has two divergent aspects, 
pro- or anti-aging dependent on stem cell type and telomerase dysfunction [25]. Further, hTERT the 
catalytic subunit of telomerase, can affect stem cell function independent of telomere maintenance in 
an  age-relevant  manner  [29].  These  complex  factors  which  we  are  only  being  to  elucidate  and 
understand  make  telomere  dysfunction  a  major  factor  in  limiting  stem  cell  function  and  
engraftment [29]. 
2.4. “Gender Matters” 
An overlooked variable in stem cell biology, gender is an important donor factor when considering 
transplantation  [35,36].  Gender  differences  in  donor  stem  cells  is  also  an  important  factor  in 
neuroprotection,  though  conclusions  on  sexual  dimorphism  mediated  neuroprotection  vary.  These 
varying  conclusions  dictate  more  understanding  of  molecular  and  cell-based  mechanisms  when 
determining host gender differences regarding neuroprotection [37–40]. Differing stem cell transplant 
studies in both human and rodent, indicate sex dimorphism in stem cells used in transplants [41].  
Yuan et al. when working with bone marrow mesenchymal stem cells proposed the need for more 
cellular  biology  studies  relating  to  underlying  gender  differences  and  their  potential  role  in 
neurogenesis [42]. Ongoing studies indicate gonadal hormones can affect neurogenesis in a gender 
specific  manner  by  influencing  growth  and  survival  [43].  Some  studies  suggest  a  general  female 
advantage applicable to stem cell transplants including potency, survival, and secretory patterns that 
may be more than hormone mediated [41]. Bianchi and Fisk raised the issue of microchimerism for 
consideration when the stem cell donor or recipient is a woman who has been pregnant [44]. This 
phenomenon also referred to as transplacental feto-maternal cell trafficking, occurs in post pregnant 
women who retain persistent  and long-term fetal cells  within their bodies either after delivery  or 
termination [44–46]. Further, this biological concept is the ultimate gender matters factor relating to 
clinical  application  for  stem  cell  therapies.  Gender  differences  create  both  multiple  and  complex 
parameters that need to be defined and understood before we can influence stem cell proliferation and 
survival during neurogenesis [41,45]. 
2.5. Mitochondrial Dynamics 
As the powerhouse of the cell, mitochondria are responsible for aerobic respiration and essential for 




few mitochondria that are heterogeneous between stem cell types. Mitochondria properties including 
subcellular and metabolic activity may act as markers of renewal, as indicated by their change in 
passaged cells [47]. While stem cells show few mitochondria in a perinuclear arrangement, senescent 
cells  show  scattered  mitochondria  throughout  the  cytoplasm  (Figure  3).  Further,  undifferentiated 
neural  stem  cells  show  low  ROS  when  compared  to  more  differentiated  cells,  while  generally 
differentiating  cells  show increased mass, increased ATP  production, and reactive oxygen species 
(ROS)  [6,47].  Overall,  differentiation  results  in  mitochondrial  changes  that  include  structure, 
morphology,  localization,  ATP  levels,  oxygen  consumption,  cellular  respiration,  and  anaerobic  
ATP production [48].  
Figure  3.  Human  neural  stem  cells  showing  mitochondria  (green)  in  progenitors  with  
(a) perinuclear staining, and (b) more cytoplasmic staining. 
 
Maintenance and repair of mitochondrial function is required throughout cellular life. However, our 
knowledge  of  mitochondria  function  in  stem  cells  is  limited  [49].  What  we  do  know  is  that 
mitochondria function is critical for energy production and protection against oxidative stress damage. 
Human ESC grows well in an environment of hypoxic conditions that maintains their pluripotency and 
resistance to spontaneous differentiation [47]. When considering stem cell manipulation and artificial 
cultivation,  our  limited  knowledge  of  mitochondria  energy  states,  biogenesis,  dynamics,  and 
degradation in stem cells present challenges of mitochondria vulnerability [49,50]. For example our 
understanding of mitochondrial status in iPS biology is rudimentary at best, and pose the question of 
how  will  a  mature  mitochondria  function  in  a  new  ―stem-like‖  state.  Further,  what  affects  will 
mitochondria age, nuclear synergy, mutations, and differentiation have on mitochondria function in 
manipulated and/or cultivated stem cells? 
 




3. Conclusions  
Identification  and  characterization  of  heterogeneity  and/or  variety  of  progenitors  and  their 
determinants is necessary for understanding their role in neuroprotection [7]. Cellular identification of 
neuronal progenitors with limited proliferative capacity subtypes and their specific stimuli is crucial 
for developing mechanistic based neuroprotective therapies that target the optimal cell type. To move 
forward in developing neuroprotectants in a calculated manner requires that we understand the stem 
cell  players  so  that  we  can  maximize  therapies  and  minimize  risks.  Growing  evidence  indicates 
important  links  in  stem  cell  function  are  mediated  by  factors  of  age,  gender,  telomerase,  and 
mitochondria. These important and inter-related characteristics are poorly understood in all stem cell 
types. Our desire to develop neuroprotectants emphasizes a need to better understand these factors and 
how they influence stem cell renewal/neurogenesis. Increased understanding of these factors provides 
insight into the best approaches, applications, and targets for stem cell therapies. How these factors 
influence  or  deregulate  functional  pathways,  can  mediate  more  efficacious  and  novel  
neuroprotective targets.  
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